Working to Eradicate Gynecologic Cancers

Anna Fagotti, PhD

Assistant Professor
St. Maria Hospital, University of Perugia
Viale Tristano di Joannuccio 1
Terni Italy 05100

Papers:
4 Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of concept 67 Chemoradiation vs. neoadjuvant chemoradiation followed by radical surgery for FIGO stage III cervical cancer: analysis of complications and 3-year survival 282 Feasibility of tertiary and quaternary cytoreduction in recurrent epithelial ovarian cancer 309 Comparison of quality of life after secondary cytoreductive surgery (SCS) ± HIPEC in recurrent ovarian cancer 329 Role of PDZ binding kinase (PBK) associated to guanylate binding protein 1 (GBP1) for drug resistance in ovarian cancer 330 The ratio between type 1 and type 2 tumor-associated macrophages predicts prognosis in patients with locally advanced cervical cancer receiving chemoradiation 366 Minimally invasive interval debulking surgery in AEOC: preliminary results from the MISSION trial Application of the laparoscopic predictive model for the prediction of complete cytoreduction in advanced epithelial ovarian cancer: the ‘Fagotti Score’ TELELAP ALF-X assisted laparoscopy for total hysterectomy: first human report Welcome Role of HIPEC therapy in advanced ovarian cancer Phase III SCORPION trial (ID number: NCT01461850) in epithelial ovarian cancer patients with high tumor load receiving PDS versus NACT: ad interim analysis on peri-operative outcome Concluding Remarks